Immunological and Differentiation Properties of Amniotic Cells Are Retained After Immobilization in Pectin Gel

Antonietta R. Silini1, Valentina Spoldi1, Silvia De Munari1, Elsa Vertua1, Fabiola Munarin2,3, Paola Petrini2,3, Silvia Fare`2,3, and Ornella Parolini1,4

Abstract
Mesenchymal stromal cells from the human amniotic membrane (i.e., human amniotic mesenchymal stromal cells [hAMSCs]) of term placenta are increasingly attracting attention for their applications in regenerative medicine. Osteochondral defects represent a major clinical problem with lifelong chronic pain and compromised quality of life. Great promise for osteochondral regeneration is held in hydrogel-based constructs that have a flexible composition and mimic the physiological structure of cartilage. Cell loading within a hydrogel represents an advantage for regenerative purposes, but the encapsulation steps can modify cell properties. As pectin gels have also been explored as cell vehicles on 3D scaffolds, the aim of this study was to explore the possibility to include hAMSCs in pectin gel. Immobilization of hAMSCs into pectin gels could expand their application in cell-based bioengineering strategies. hAMSCs were analyzed for their viability and recovery from the pectin gel and for their ability to differentiate toward the osteogenic lineage and to maintain their immunological characteristics. When treated with a purposely designed pectin/hydroxyapatite gel biocomposite, hAMSCs retained their ability to differentiate toward the osteogenic lineage, did not induce an immune response, and retained their ability to reduce T cell proliferation. Taken together, these results suggest that hAMSCs could be used in combination to pectin gels for the study of novel osteochondral regeneration strategies.

Keywords
human placenta, amniotic membrane, amniotic mesenchymal stromal/stem cells, pectin gel, osteochondral defects

Introduction
Osteochondral defects resulting from congenital defects, pathological disorders, and/or traumatic injury represent a major clinical problem with lifelong chronic pain and compromised quality of life1,2. Due to its poor regenerative capacity, stratified architecture, and disparate biochemical properties, the challenge remains to replicate robust integration of cartilage and subchondral bone and the complex stratified tissue3,4.

Bioengineered scaffolds are being widely investigated for osteochondral regeneration strategies. Various scaffolds, such as porous sponges5–7, meshes, and hydrogels8, have been prepared from biodegradable synthetic and natural polymers for tissue engineering applications9 and have been shown to influence cell functions and improve cartilage, osteochondral, and bone regeneration. Among the different properties of scaffolds, a flexible structure mimicking the physiological structure of cartilage is essential. In this perspective, great promise for osteochondral regenerative medicine is entrusted in hydrogel-based structures8,10,11 that can be obtained by the use of natural polymers. Among them, pectins, a family of polysaccharides found in the primary cell walls of plant cells, are commonly used in drug delivery and wound-healing applications12–15. Embedding cells in a hydrogel has several...
advantages. First, considering cell delivery for regenerative purposes, the presence of a gel has the advantage of confining cells in a specific site and fitting/adapting them to the specific defect, while at the same time insulating and protecting the cells from the surrounding microenvironment. Second, it can also allow processing techniques which are commonly used to obtain graded scaffolds, such as preparing cell-loaded hydrogel sheets, impregnating porous structures with the cell-loaded gel, and production of multilayered scaffolds.

Current developments in tissue engineering strategies for articular cartilage regeneration focus on the design of supportive 3-dimensional (3-D) scaffolds and their use in combination with cells from different sources. Mesenchymal stromal cells (MSCs) have been widely investigated in tissue engineering strategies for articular cartilage regeneration. MSCs possess extensive proliferation potential and proven capability to differentiate along the osteochondral pathway. In addition to proliferation and multilineage differentiation potential, MSCs possess immune-modulatory and anti-inflammatory functions, which may enhance their regenerative power.

While MSCs from bone marrow are widely used, more recently, MSCs from human term placenta have gained attention due to their unique properties. After birth, the placenta is usually discarded as nothing more than biological waste, and thus placental tissue is easily accessible in a noninvasive way. Furthermore, compared to MSCs from other sources such as bone marrow and adipose tissue, high cell recovery is possible from placental tissues. Human placenta is composed of a fetal part, including the amnion, chorion, umbilical cord, and a maternal part, termed decidua. Within these components, different cell subpopulations with mesenchymal characteristics may be isolated, and as established by the consensus of the First International Workshop on Placenta-Derived Stem Cells, they are referred to human amniotic mesenchymal stromal cells (hAMSCs) and human chorion mesenchymal stromal cells. Nowadays, it has been widely demonstrated that some cells from the human placenta possess some stem/progenitor cell potential which is thought, at least in part, to be due to the early origin of placental tissues during embryogenesis and prior to gastrulation. In addition, placental MSCs, and more specifically MSCs from the amniotic membrane, possess intrinsic immune-modulatory properties which do not require licensing with inflammatory stimuli as suggested with MSCs from bone marrow.

The aim of this study is to evaluate hAMSC in vitro properties after pectin gel treatment to establish whether hAMSCs could be ideal candidates for cell-based bioengineering strategies using pectin gels as cell vehicles on 3-D scaffolds. First, we investigated hAMSC recovery and cell viability after loading into a pectin gel. Then, we investigated whether hAMSCs retained their unique functional properties, such as the inability to mount an immune response, ability to decrease the proliferation of activated peripheral blood mononuclear cells (PBMCs), and to differentiate toward the osteogenic lineage.

We conclude that pectin gel treatment does not alter hAMSCs and does not influence their immunological properties nor osteogenic differentiation, suggesting that hAMSCs could be used in combination with pectin gels obtained in the reported conditions for the study of novel osteochondral regeneration strategies.

Materials and Methods

Ethics Statements

All samples used in this study were obtained after informed consent from donors. For human term placenta and peripheral blood samples, written informed consent to collect placenta and isolate human amniotic-derived cells was obtained from each single donor according to the guidelines of the Ethics Committee (Comitato Etico Provinciale) of the province of Brescia.

Human MSC Isolation, Growth, and Cryopreservation

Human term placentas (n = 12) were processed within approximately 8 h after birth. The amnion was manually separated from the chorion and washed extensively in saline sodium chloride 0.9% with 100 U/mL penicillin and 100 μg/mL streptomycin (herein referred to as P/S, both from Sigma-Aldrich, St. Louis, MO, USA) and 2.5 mg/mL amphotericin B (Sigma-Aldrich). Afterward, the amnion was cut into small fragments (~3 × 3 cm²) which were decontaminated by a brief incubation in saline sodium chloride 0.9% + 2.5% Betadine − 0.25% Iodopovidone (Betadine-Esojod 10%, Ecolab-Esoform, Venice, Italy) and 3 min in phosphate-buffered saline (PBS; Sigma-Aldrich) containing 500 U/mL penicillin, 500 μg/mL streptomycin, 12.5 μg/mL amphotericin B, and 1.87 mg/mL Cefamezin (Teva, Italy). The amnion fragments were then incubated for 9 min at 37°C in HBSS (Sigma-Aldrich) containing 2.5 U/mL dispase (VWR, Milan, Italy). After a 3 to 5 min resting period at room temperature in Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma-Aldrich) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Sigma-Aldrich), 2 mM L-glutamine (Sigma-Aldrich), and P/S, the fragments were digested with 0.94 mg/mL collagenase (Roche, Mannheim, Germany) and 0.01 mg/mL DNase (Roche) for 2.5 h at 37°C. Amnion fragments were then incubated for 10 min. The cell suspension was filtered a second time with a 70-μm strainer (BD Falcon). Cells were thawed in 90% heat-inactivated FBS and 10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich) in liquid nitrogen until use.

To obtain hAMSCs at passage 1, freshly isolated or thawed cells were plated in flasks (Corning Inc, Corning, NY, USA) at a density of 10,000 cells/cm² in CHANG Medium C supplemented with 2 mM L-glutamine and P/S. Upon reaching subconfluence, adherent cells were washed in PBS, detached with 0.25% trypsin (Sigma-Aldrich), and then cultured for subsequent experiments.
Cell viability and recovery were analyzed using the trypan blue exclusion assay.

**hAMSC Loading into the Pectin Gel**

Low-methoxyl pectin (CU701, kindly provided by Herbstreith & Fox, Nuremberg, Germany) was dissolved overnight in a sterile NaCl (10.8 mg/mL; Sigma-Aldrich) – NaHCO3 (2.52 mg/mL; Sigma-Aldrich) solution at a final concentration of 22.5 mg/mL. Calcium phosphate (CaP; kindly provided by Eurocoating SpA [Italy], hydroxyapatite granules, in the range 20 to 40 μm) was suspended in water to obtain a final concentration of 23 mM.

CaP suspension (0.4 mL) was mixed with pectin solution (2 mL) and 5 × 10^5 hAMSCs were added by resuspension in 0.4 mL of complete medium (DMEM [Sigma] + 20% FBS), using a dual-syringe system. Afterward, 0.4 mL aliquots of the hAMSC–pectin gel suspension were plated in 24-well plates (Corning) and incubated for 30 s with 0.1 mL of 2% w/v of calcium gluconate (Sigma). Complete medium (0.5 mL) was added to each well and the plates were incubated at 37°C and 5% CO2 for different time points (1, 3, 24, 48, 72, and 168 h). As controls, hAMSCs were mixed and plated in complete culture medium (Dulbecco’s modified Eagle’s medium (DMEM) + 20% FBS) using a dual-syringe system or, to mimic the gel consistency of pectin, in Matrigel™ Basement Membrane Matrix (BD Biosciences). At the end of incubation, 1 mL of PBS + 25% ethylenediaminetetraacetic acid (EDTA) 0.5 M was added to each well to dissolve the pectin gel. Prior to immunological and differentiation assays, CaP was depleted using density gradient centrifugation (Histopaque; Sigma-Aldrich) due to its interference in these assays.

**Osteogenic Differentiation**

For the treatment conditions described above, hAMSCs (1 × 10^5/cm²) were seeded in DMEM + 20% FBS + P/S + L-glutamine. Three days later, culture medium was substituted with Stempro Osteo/Chondrocyte Diff Basal Medium with osteogenic supplement (Life Technologies). For controls, culture medium was substituted with fresh medium. Culture medium was changed twice a week. Osteogenic differentiation was assessed after 14 d and calcium deposits were visualized using the Alizarin Red (Sigma-Aldrich) and Von Kossa (Bio Optica) stainings. Cells were fixed in 10% formalin and 2% Alizarin Red pH 4.2 was added, left for 25 min, and afterward cells were washed with distilled water. Alternatively, cells were fixed in 10% formalin and 5% silver nitrate (Sigma-Aldrich) was added for 1 h under ultraviolet light, washed with water, and incubated with 5% sodium thiosulfate (Sigma-Aldrich) for 5 min and washed once more.

**Immunological Studies**

The ability of hAMSCs to either induce a T-cell response or inhibit the proliferation of PBMCs activated with anti-CD3 was performed as previously described. PBMCs were obtained from heparinized whole blood samples or buffy coats from healthy subjects using density gradient centrifugation (Histopaque; Sigma-Aldrich).

PBMCs (1 × 10^5/well in a 96-well plate) were cultured with hAMSCs (PBMC:hAMSC ratios 1:1, 1:0.5, 1:0.1, 1:0.02, and 1:0.004) or were stimulated with 125 ng/mL (final concentration) α-CD3 (Orthoclone OKT3, Janssen-Cilag) in the presence of hAMSCs (PBMC:hAMSC ratios 1:1, 1:0.5, and 1:0.1). All conditions were performed in triplicate in DMEM (Sigma-Aldrich) supplemented with 20% heat-inactivated FBS, 2 mM L-glutamine, and P/S. After 3 d of culture, lymphocyte proliferation was assessed by adding 0.67 μCi of [3H]-thymidine (INC Biomedicals) per well. Sixteen to 18 h after the addition of thymidine, cell cultures were harvested with a FilterMate Harvester (PerkinElmer), and thymidine incorporation was measured using a microplate scintillation and luminescence counter (Top Count NXT; PerkinElmer).

Lymphocyte proliferation was examined in the presence of irradiated (3,000 cGy) hAMSCs (0.1 × 10^5/well, 0.5 × 10^5/well, and 1 × 10^5/well) in contact with activated PBMCs.

**Statistical Analysis**

All data are expressed as mean ± standard error of the mean (SEM). All statistical analyses were performed using GraphPad Prism version 6.00 for Windows (Graph-Pad Software, San Diego, CA, USA). Analysis of cell recovery and viability was performed using an analysis of variance (ANOVA) or unpaired t-test. Comparison of counts per minute values between hAMSCs and PBMC activated with α-CD3 was performed using an ANOVA.

**Results**

**hAMSC Recovery and Viability After Loading into Pectin Gel**

We investigated whether loading hAMSCs into pectin gel (pectin and CaP) altered cell recovery and viability. First, we cultured hAMSCs in pectin gel or in complete culture medium (DMEM + 20%FBS) for different time intervals, from 1 h up to 7 d. As an additional control to mimic the gel consistency of pectin, hAMSCs were also cultured in Matrigel™ basement membrane matrix. After incubation in EDTA to remove pectin gel, residual fragments of the gel were observed and the concentration of EDTA was progressively increased up to 5 M during the development of the cell recovery protocols, indicating a strong interaction of the pectin chains with Ca^{2+} cross-linker. Sodium citrate was not effective for the dissolution of the gels.

We detected a 50% drop in cell recovery after 1 h of incubation within the pectin gel; this did not decrease further and remained constant for up to 7 d after incubation (Fig. 1A). In addition, no effects on hAMSC viability were
observed for up to 24 h after incubation within pectin gel when compared to untreated hAMSCs at time 0 (T0; Fig. 1B). There was a small, but significant, decrease in hAMSC viability only 48 and 72 h after incubation in pectin gel, but viability began to increase again 7 d after incubation within pectin gel when compared to untreated hAMSCs at T0 (Fig. 1B). Cell viability decreased from 83% at T0 (before loading into pectin gel) to 58% after a 7-d treatment with pectin gel. Cell recovery was similar between all the considered time points, thus subsequent studies were performed using a 3-h treatment within the pectin gel.

The recovery and viability of hAMSCs cultured in complete culture medium decreased continuously up to 24 h after culture, likely due to the stress induced by the dual-syringe system used to mix the cell suspension, but then slowly began to increase until the end of the analysis (168 h; Fig. 1A). hAMSC viability decreased from 83% at T0 (before loading into pectin gel) to 58% after a 7-d treatment with pectin gel. Cell recovery was similar between all the considered time points, thus subsequent studies were performed using a 3-h treatment within the pectin gel.

Clinical use of MSCs often requires cell expansion to obtain a high number of cells for injection into patients. Thus, we analyzed the effects of immobilization within pectin gel on culture-expanded hAMSCs. As shown in Fig. 1, pectin gel did not alter the recovery (Fig. 1C) or viability (Fig. 1D) of hAMSCs at passage 1, thus subsequent experiments were performed using hAMSCs at passage 1.

Immunological Properties and Osteogenic Differentiation Capabilities of hAMSCs After Loading into Pectin Gel

Since the low immunogenicity and immunomodulatory properties of hAMSCs are well-documented\textsuperscript{24–32} and have been linked to their use in allogeneic settings and therapeutic effects in preclinical models of inflammatory-based diseases\textsuperscript{33}, we next sought to investigate whether loading into pectin gel altered these properties. Pectin gel loading had no effect on the inability of hAMSCs to induce a T cell proliferative response (Fig. 2A). Also, as shown in Fig. 2B, hAMSCs and pectin gel-loaded hAMSCs were both able to significantly inhibit anti-CD3-activated PBMCs when cultured in contact with each other at the 2 highest hAMSC concentrations used (activated PBMC:hAMSC ratios of 1:0.5 and 1:1). No significant differences were observed in the ability to inhibit T cell proliferation between hAMSCs alone and hAMSCs loaded into pectin gel (Fig. 2B).

We also investigated the differentiation ability of hAMSCs toward the osteogenic lineage after loading within pectin gel using Alizarin Red and von Kossa stainings (Fig. 2C). There were no qualitative differences in the degree of differentiation between untreated hAMSCs and hAMSCs loaded into the gel.
Discussion and Conclusions

This is the first study investigating MSCs from the amniotic membrane of human term placenta as potential cell candidates in 3-D scaffolds using pectin gel cell carrier. MSCs from the amniotic membrane present unique characteristics; they are easily accessible in a noninvasive way, and they possess intrinsic immune-modulatory properties which do not require licensing with inflammatory stimuli as suggested with MSCs from bone marrow\(^34\). Thus, amniotic membrane MSCs could represent attractive candidates in tissue engineering strategies for osteochondral defect regeneration in combination to 3-D scaffolds.

Cell immobilization, and ultimately the limited exposure to cell culture media, may alter the properties of cells such as the cell viability. Recently, pectin gels have shown interesting properties toward bone regeneration\(^15\) and promotion of mineralization\(^15\). Pectin microcapsules\(^15\) and injectable gels\(^36\) modified with arginylglycylaspartic acid (RGD)-containing peptides have demonstrated their ability to maintain viability of cells embedded within the gels, both in vitro and in vivo\(^36\). The properties of the pectin gels can be controlled by finely tuning the cross-linking process\(^37\). Among pectin gels, CaPs/pectin gels have been previously produced by exploiting the double effect of cross-linker and filler to produce biocomposite gels\(^38,39\) or by incorporating nano-hydroxyapatite to support osteoblast growth\(^40\). The addition of pectin in bone cements, based on CaPs, has been shown to improve the adhesion and proliferation of human adipose tissue-derived stem cells\(^41\).

Herein, we sought to investigate whether hAMSCs and CaP/pectin gel that includes CaP as a biomimetic compound could be compatible partners in cell-based bioengineering strategies. Thus, the focus of this study was to define whether pectin gel did not alter viability and characteristics of amniotic cells.

When hAMSCs were encapsulated in the pectin gel, cell recovery dropped by 50\% after 1 h of incubation, and the recovery remained stable (50\%) at all considered time points. Since no further decrease of cell viability was observed during
the incubation, the drop in cell viability after 1 h is likely due
to a possible incomplete dissolution of the gel, thus causing an
underestimation of the number of cells, as it was possible to
observe fragments and deposits after the centrifugation step.
The gel environment was able to support cell viability in
agreement with the previous research on different pectin gel
formulations. Interestingly, the immunological properties of hAMSCs,
that is, their inability to induce a T cell response and their ability to inhibit the proliferation
of PBMCs activated with anti-CD3, were retained thus indicat-
ing that amniotic cells were able to produce the modulatory
bioactive molecules even after loading into pectin gel. In
addition, the presence of extracellular calcium deposits
indicates a mature osteoblast cell function, supporting the hypoth-
thesis of the retention of the capability of hAMSCs to
differentiate toward the osteogenic lineage. These aspects
could be considered key features to exploit the potential of
amniotic MSCs toward the development of novel osteochon-
dral regeneration strategies, using a carrier that does not alter
hAMSCs intrinsic properties, such as their immunological and
differentiation properties. The possibility to embed hAMSCs
within a gel is a fundamental achievement to expand the
potential applications of these cells in tissue regeneration.

Acknowledgment
The authors would like thank Fondazione Poliambulanza Istituto
Ospedaliero, Brescia (Italy), and the Cariplo Foundation (grant no.
2012-0842) for their support.

Ethical Approval
This study was approved by our institutional review board.

Statement of Human and Animal Rights
The study includes human term placenta and peripheral blood sam-
ple from human subjects. All samples used in this study were
obtained after informed consent from donors. Written informed
consent to collect placenta and isolate human amniotic-derived
cells was obtained from each single donor according to the guide-
lines of Ethics Committee (Comitato Etico Provinciale) of the prov-
ence of Brescia.

Statement of Informed Consent
All samples used in this study were obtained after informed consent
from donors. Written informed consent to collect placenta and iso-
late human amniotic-derived cells was obtained from each single
donor according to the guidelines of Ethics Committee (Comitato
Etico Provinciale) of the province of Brescia.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support
for the research, authorship, and/or publication of this article:
This work is supported by Fondazione Poliambulanza Istituto Ospeda-
liero and the Cariplo Foundation (grant no. 2012-0842).

References
1. Magill P, Byrne DP, Baker JF, Mulhall KJ. Review article: osteochondral reconstruction and grafting. J Orthop Surg (Hong Kong). 2011;19(1):93–98.
2. Zhang L, Hu J, Athanasiou KA. The role of tissue engineering in articular cartilage repair and regeneration. Crit Rev Biomed Eng. 2009;37(1–2):1–57.
3. Madry H, van Dijk CN, Mueller-Gerb M. The basic science of the subchondral bone. Knee Surg Sports Traumatol Arthrosc. 2010;18(4):419–433.
4. Kawcak CE, McIlwraith CW, Norrbin RW, Park RD, James SP. The role of subchondral bone in joint disease: a review. Equine Vet J. 2001;33(2):120–126.
5. Nava MM, Draghi L, Giordano C, Pietrabissa R. The effect of scaffold pore size in cartilage tissue engineering. J Appl Biomater Funct Mater. 2016;14(3):e223–e229.
6. Fare S, Bertoldi S, Meskinfam M, Spoldi V, Tanzi MC, Par-olini O. Biomimetic hybrid scaffolds for osteo-chondral tissue repair: design and osteogenic differentiation of human placenta-derived cells (hPDC). Conf Proc IEEE Eng Med Biol Soc. 2015;2015:1753–1756. doi:10.1109/EMBC.2015.7538220.
7. Raimondi MT, Bertoldi S, Caddeo S, Farè S, Arrigoni C, Mor-etti M. The effect of polyurethane scaffold surface treatments on the adhesion of chondrocytes subjected to interstitial perfusion culture. Tissue Eng Regen Med. 2016;13(4):364–374.
8. Coluccino L, Stagnaro P, Vassalli M, Scaglione S. Bioactive TGF-beta/HA alginate-based scaffolds for osteochondral tissue repair: design, realization and multilevel characterization. J Appl Biomater Funct Mater. 2016;14(1):e42–e52.
9. Scaffaro R, Lopresti F, Maio A, Sutera F, Botta L. Develop-
ment of polymeric functionally graded scaffolds: a brief review. J Appl Biomater Funct Mater. 2017;15(2):e107–e121.
10. Martin I, Miot S, Barbero A, Jakob M, Wendt D. Osteochon-
dral tissue engineering. J Biomech. 2007;40(4):750–765.
11. Chu J, Zeng S, Gao L, Groth T, Li Z, Kong J, Zhao M, Li L. Poly (L-lactic acid) porous scaffold-supported alginate hydrogel with improved mechanical properties and biocompatibility. Int J Artif Organs. 2016;39(8):435–443.
12. Munarin F, Tanzi MC, Pettrini P. Advances in biomedical appli-
cations of pectin gels. Int J Biol Macromol. 2012;51(4):681–689.
13. Vergaro V, Papadia P, Pettrini P, Fanizzi FP, De Pascali SA, Baldassarre F, Pastorino L, Ciccarella G. Nanostructured polysaccharide microcapsules for intracellular release of cisplatin. Int J Biol Macromol. 2017;99:187–195. doi:10.1016/j.ijbiomac.2017.02.066.
14. Pastorino L, Erokhina S, Ruggiero C, Erokhin V, Pettrini P. Fabrication and characterization of chitosan and pectin nanostructured multilayers. Macromol Chem Phys. 2015;216(10):1067–1075.
15. Munarin F, Pettrini P, Tanzi MC, Barbosa MA, Granja PL. Biofunctional chemically modified pectin for cell delivery. Soft Matter. 2012;8(17):4731–4739.
16. Munarin F, Pettrini P, Bozzini S, Tanzi MC. New perspectives in cell delivery systems for tissue regeneration: natural-derived injectable hydrogels. J Appl Biomater Funct Mater. 2012;10(2):67–81.
17. Radhakrishnan J, Subramanian A, Krishnan UM, Sethuraman S. Injectable and 3D bioprinted polysaccharide hydrogels: from cartilage to osteochondral tissue engineering. Biomacromolecules. 2017;18(1):1–26.

18. Penolazzi L, Mazzitelli S, Vecchiatini R, Torreggiani E, Lambertini E, Johnson S, Badyak SF, Piva R, Naструктор C. Human mesenchymal stem cells seeded on extracellular matrix-scaffold: viability and osteogenic potential. J Cell Physiol. 2012;227(2):857–866.

19. Nooeaid P, Salih V, Beier JP, Boccaccini AR. Osteochondral tissue engineering: scaffolds, stem cells and applications. J Cell Mol Med. 2012;16(10):2247–2270.

20. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317.

21. Parolini O, Alviano F, Bagnara GP, Bilić G, Buhring HJ, Evangelista M, Hennerbichler S, Liu B, Magatti M, Mao N, et al. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells. 2008;26(2):300–311.

22. Can A, Karahusyeinoglu S. Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells. 2007;25(11):2886–2895.

23. Shi Y, Su J, Roberts AI, Shou P, Rabson AB, Ren G. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol. 2012;33(3):136–143.

24. Magatti M, De Munari S, Vertua E, Gibelli L, Wengler GS, Parolini O. Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities. Stem Cells. 2008;26(1):182–192.

25. Pischitutta F, Brunelli L, Romele P, Silini A, Sammali E, Paracchini L, Marchini S, Talamini L, Bigini P, Boncoraglio GB, et al. Protection of brain injury by amniotic mesenchymal stromal cell-secreted metabolites. Crit Care Med. 2016;44(11):e1118–e1131.

26. Magatti M, Vertua E, De Munari S, Caro M, Caruso M, Silini A, Delgado M, Parolini O. Human amnion favours tissue repair by inducing the M1-to-M2 switch and enhancing M2 macrophage phenotypes. Cell Transplant. 2015;24(9):1733–1752. doi: 10.3727/096368914X684033

27. Pianta S, Bonassi Signoroni P, Muradore I, Rodrigues MF, Rossi D, Silini A, Parolini O. Amniotic membrane mesenchymal cells-derived factors skew T cell polarization toward Treg and downregulate Th1 and Th17 cells subsets. Stem Cell Rev. 2015;11(3):394–407.

28. Magatti M, Caruso M, De Munari S, Vertua E, De D, Manuelpillai U, Parolini O. Human amniotic membrane-derived mesenchymal and epithelial cells exert different effects on monocye-derived dendritic cell differentiation and function. Cell Transplant. 2015;24(9):1733–1752.

29. Cargnoni A, Piccinelli EC, Ressel L, Rossi D, Magatti M, Toschi I, Cesari V, Albertini M, Mazzola S, Parolini O. Conditioned medium from amniotic membrane-derived cells prevents lung fibrosis and preserves blood gas exchanges in bleomycin-injured mice-specificity of the effects and insights into possible mechanisms. Cytotherapy. 2014;16(1):17–32.

30. Parolini O, Souza-Moreira L, O’Valle F, Magatti M, Hernandez-Cortes P, Gonzalez-Rey E, Delgado M. Therapeutic effect of human amniotic membrane-derived cells on experimental arthritis and other inflammatory disorders. Arthritis Rheumatol. 2014;66(2):327–339.

31. Cargnoni A, Ressel L, Rossi D, Poli A, Arienti D, Lombardi G, Parolini O. Conditioned medium from amniotic mesenchymal tissue cells reduces progression of bleomycin-induced lung fibrosis. Cytotherapy. 2012;14(2):153–161.

32. Magatti M, De Munari S, Vertua E, Nassauro C, Albertini A, Wengler GS, Parolini O. Amniotic mesenchymal tissue cells inhibit dendritic cell differentiation of peripheral blood and amnion resident monocytes. Cell Transplant. 2009;18(8):899–914.

33. Silini AR, Magatti M, Cargnoni A, Parolini O. Is immune modulation the mechanism underlying the beneficial effects of amniotic cells and their derivatives in regenerative medicine? Cell Transplant. 2017;26(4):531–539.

34. Rossi D, Pianta S, Magatti M, Sedlmayr P, Parolini O. Characterization of the conditioned medium from amniotic membrane cells: prostaglandins as key effectors of its immunomodulatory activity. PLoS One. 2012;7(10):e46956.

35. Munarin F, Giuliano L, Bozzini S, Tanzi MC, Petrini P. Mineral phase deposition on pectin microspheres. Mater Sci Eng C. 2010;30(3):491–496.

36. Neves SC, Gomes DB, Sousa A, Bidarre SJ, Petrin P, Moroni L, Barrias CC, Granja PL. Biofunctionalized pectin hydrogels as 3D cellular microenvironments. J Mater Chem B. 2015;3(10):2096–2108.

37. Secchi E, Munarin F, Alaimo MD, Bosiso S, Buzzacaro S, Ciccarella G, Vergaro V, Petrini P, Piazza R. External and internal gelation of pectin solutions: microscopic dynamics versus macroscopic rheology. J Phys Condens Matter. 2014;26(46):464106.

38. Munarin F, Petrini P, Gentilini R, Pillai RS, Dire S, Tanzi MC. Reactive hydroxyapatite fillers for pectin biocomposites. Mater Sci Eng C Mater Biol Appl. 2014;45:154–161. doi:10.1016/j.msec.2014.09.003

39. Munarin F, Petrini P, Barcellona G, Roversi T, Piazza L, Visai L, Tanzi MC. Bioactive hydroxyapatite fillers for pectin bio-composites. Mater Sci Eng C Mater Biol Appl. 2014;45:154–161. doi:10.1016/j.msec.2014.09.003

40. Sumathra M, Govindaraj D, Jayaraj M, Al Arafaj A, Munusamy MA, Kumar SS, Rajan M. Sustainable pectin fascinating hydroxyapatite nanocomposite scaffolds to enhance tissue regeneration. Sustain Chem Pharm. 2017;5(Suppl. C):46–53. doi:10.1016/j.jibio.2017.02.001

41. Zhao L, Li J, Zhang L, Wang Y, Wang J, Gu B, Chen J, Hao T, Wang C, Wen N. Preparation and characterization of calcium phosphate/pectin scaffolds for bone tissue engineering. RSC Adv. 2016;6(67):62071–62082.